Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27293430 | 0.87 | LMNA (0.34) | LMNAMEN1KMT2AHTR2ARELA | |
| SCHEMBL11410075 | 0.83 | TSHR (0.45) | LMNAMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL314557 | 0.78 | HTR2A (0.41) | LMNAMEN1KMT2AHTR2ARELA | |
| SCHEMBL7950808 | 0.78 | SIGMAR1 (0.41) | MEN1KMT2AMAOBL3MBTL1 | |
| SCHEMBL10497155 | 0.76 | LMNA (0.46) | LMNAMEN1KMT2AHTR2ARELA | |
| SCHEMBL9426848 | 0.76 | MEN1 (0.51) | LMNAMEN1KMT2AHTR2ARELA | |
| SCHEMBL28101030 | 0.76 | HTR2A (0.44) | LMNAMEN1KMT2AHTR2ARELA | |
| SCHEMBL14910835 | 0.75 | LMNA (0.45) | LMNAMEN1KMT2AHTR2ARELA | |
| SCHEMBL6597173 | 0.74 | LMNA (0.38) | LMNAALDH1A1TSHR | |
| SCHEMBL27901751 | 0.73 | LMNA (0.40) | LMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101098878-B | Monophosphine compounds, transition metal complexes thereof and preparation of optically active compounds using the complexes as asymmetric catalysts | SUMITOMO CHEMICAL CO | 2013-10-16 | — | — | CN | disclosed |
| US-20110301146-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110263566-A1 | 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364087-A1 | 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES AND PBK INHIBITORS CONTAINING THE SAME | Oncotherapy Science, Inc. (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-2358365-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | Oncotherapy Science, Inc. (JP) | 2011-08-24 | — | — | EP | disclosed |
| CN-102076653-A | Process for producing optically active amine compound | SUMITOMO CHEMICAL CO | 2011-05-25 | — | — | CN | disclosed |
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| WO-2010058512-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | ONCOTHERAPY SCIENCE, INC. (JP) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010051085-A1 | 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2010-05-06 | — | — | WO | disclosed |
| CN-101098878-A | Monophosphine compounds, transition metal complexes thereof and preparation of optically active compounds using the complexes as asymmetric catalysts | ERICK M CARREIRA (JP) | 2008-01-02 | — | — | CN | disclosed |
| EP-1773853-A1 | MONOPHOSPHINE COMPOUNDS, TRANSITION METAL COMPLEXES THEREOF AND PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS USING THE COMPLEXES AS ASYMMETRIC CATALYSTS | Sumitomo Chemical Company, Limited (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121157-A1 | MONOPHOSPHINE COMPOUNDS, TRANSITION METAL COMPLEXES THEREOF AND PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS USING THE COMPLEXES AS ASYMMETRIC CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
| CN-1525968-A | composition for preventing or treating liver disease | 三共株式会社 | 2004-09-01 | — | — | CN | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | LMNA 3973/4885MEN1 444/4885KMT2A 2019/4885 |
| US-20110263566-A1 | 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK Inhibitors Containing the Same | PDXK, BCKDK, SBK1 | LMNA 1315/4885MEN1 2904/4885KMT2A 1937/4885 |
| US-20110301146-A1 | GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES | GSK3B, GSK3A, GYS2 | LMNA 553/4885MEN1 2637/4885KMT2A 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.